Talk:Adrenergic beta-antagonist

Second paragraph of the introduction -- more needed?

The second sentence of the second paragraph of the introduction reads

Beta-blockers that have low intrinsic sympathomimetic activity (ISA), low membrane stabilizing activity, high beta 1-selectivity, and high lipophilicity may be more effective

Effective for all indications, or, as the citation seems to suggest, for increased survival in at least some types of cardiovascular disease, or just the labeled indications (for metoprolol at least): Acute Coronary Syndrome, Chronic Angina Pectoris, Hypertension, Myocardial Infarction, Myocardial Reinfarction Prevention.

Are these characteristics true for all indications, such as migraine prophylaxis, benign intentional tremor, heart failure, hypertrophic cardiopathy, mitral valve prolapse, thyrotoxicosis, etc.?Howard C. Berkowitz 21:56, 3 January 2009 (UTC)

Maybe this isn't the place for it, but adrenergic vs. sympathomimetic

I'd really like to see an elegant exposition of the differences between the new and the old terms, the old rephrased in agonist-antagonist terms and more specific receptors. It's one of those things that I can use, but I can't explain as well as I would like. Howard C. Berkowitz 14:06, 20 June 2009 (UTC)

i love the timeline because it highlights age and generic - also insight for reserach timeline

research is only done on protected drugs, not usually on generics. So it's great to know timelines like this one. Please include date of patent for all drugs posted on citizendium! Even if they get extended, it is still useful to know when the patent started and then I can estimate approximately how many years will be left before the drug is generic. Tom Kelly 03:26, 31 August 2009 (UTC)